Stem Cell Transplant w/Laronidase for Hurler
Phase 2
Completed
- Conditions
- Mucopolysaccharidosis IHurler Syndrome
- Interventions
- Procedure: Stem Cell Transplant
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2019-07-11
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 25
- Registration Number
- NCT00176891
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Stem Cell Transplant for Immunologic or Histiocytic Disorders
Phase 2
Completed
- Conditions
- Hemophagocytic LymphohistiocytosisX-Linked Lymphoproliferative DisordersImmunologic Deficiency SyndromesChediak-Higashi SyndromeGriscelli SyndromeLangerhans-Cell Histiocytosis
- Interventions
- Procedure: Stem Cell TransplantDrug: Anti-thymocyte globulin (ATG)
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 19
- Registration Number
- NCT00176865
- Locations
- 🇺🇸
Masonic Cancer Center University of Minnesota, Minneapolis, Minnesota, United States
Stem Cell Transplant for Hematological Malignancy
Not Applicable
Terminated
- Conditions
- Leukemia, Lymphocytic, ChronicJMMLLeukemia, Myeloid, ChronicAMLMDSNon-hodgkin's LymphomaLeukemia, Lymphocytic, AcuteMultiple MyelomaHodgkin's Disease
- Interventions
- Biological: Stem Cell TransplantRadiation: Total Body IrradiationBiological: CD4+/CD25+ cellsDrug: Equine ATG (ATGAM)
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2021-01-22
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 330
- Registration Number
- NCT00176930
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Autologous Transplant for Multiple Myeloma
Phase 2
Completed
- Conditions
- Multiple Myeloma
- Interventions
- Procedure: Stem Cell TransplantBiological: Granulocyte-colony stimulating factor
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 363
- Registration Number
- NCT00177047
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Post Transplant Donor Lymphocyte Infusion
Phase 2
Terminated
- Conditions
- Multiple MyelomaMyelodysplastic SyndromeLeukemia, Lymphocytic, AcuteLymphomasLeukemia, Myeloid, ChronicLeukemia, Lymphocytic, ChronicAML
- Interventions
- Procedure: Donor Lymphocyte InfusionDrug: Induction Chemotherapy
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2019-07-30
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 57
- Registration Number
- NCT00167180
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)
Phase 1
Completed
- Conditions
- Juvenile Myelomonocytic Leukemia
- Interventions
- Biological: Stem Cell TransplantDrug: Preparative Regimen
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 15
- Registration Number
- NCT00167219
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Stem Cell Transplantation for Fanconi Anemia
Phase 1
Terminated
- Conditions
- Fanconi Anemia
- Interventions
- Procedure: Hematopoietic Stem Cell TransplantProcedure: Thymic Shielding During RadiationProcedure: Total Body Irradiation
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2019-08-26
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 16
- Registration Number
- NCT00167206
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) Leukemia
Not Applicable
Completed
- Conditions
- MDSAMLLeukemia, Lymphocytic, AcuteLeukemia, Myeloid, Chronic
- Interventions
- Procedure: Donor Lymphocyte Infusion
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 40
- Registration Number
- NCT00167167
- Locations
- 🇺🇸
University of Minnesota Medical Center, Minneapolis, Minnesota, United States
Safety Study of an Immune Response Modifier in Patients With Refractory Solid Organ Tumors
Phase 1
Completed
- Conditions
- Neoplasms
- First Posted Date
- 2004-11-02
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 42
- Registration Number
- NCT00095160
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
Biological Therapies Following Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Advanced Breast Cancer
Phase 1
Terminated
- Conditions
- Breast CancerLymphoma
- First Posted Date
- 2004-06-21
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Registration Number
- NCT00005993
© Copyright 2025. All Rights Reserved by MedPath